NEWTON, Mass.--(BUSINESS WIRE)--Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will host the Galectin Science and Therapeutic Applications Symposium, September 17-19, 2012, in Boston, Massachusetts. The symposium will bring together scientific and medical experts to explore the role of galectins in disease and discuss their promise as drug candidates through translational and clinical data. Galectins are important therapeutic targets because they mediate fundamental biologic mechanisms in many pathological processes, including fibrosis, cancer and heart and lung diseases.
